Rapid Antibody Advances Will Leverage Secular Pandemic Trends
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
21 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$5.00
89.6% undervalued intrinsic discount21 Aug
US$0.52
1Y
-48.5%7D
-26.4%